This study is for people with pulmonary embolism (PE), which is a blood clot in the lungs. It's comparing two ways to treat PE: one group will receive standard blood thinners (anticoagulant therapy) only, and the other group will receive blood thinners plus a procedure called catheter-directed therapy (CDT). CDT involves using a catheter to either remove the clot mechanically (mechanical thrombectomy) or deliver clot-dissolving medicine directly to the clot (catheter-directed thrombolysis). The study wants to see if CDT improves how well your body uses oxygen and your physical ability, and if it increases the risk of major bleeding. You might be able to join if you are 18 or older, have symptomatic PE in a main or lobar artery, and your heart's right ventricle is enlarged. The study plans to enroll 500 participants, but its current status is unclear.

Study design

This is an open-label, assessor-blinded, randomized study comparing catheter-directed therapy plus anticoagulation to anticoagulation alone, involving 500 participants.

What's involved

You would receive anticoagulant therapy for at least 3 months. If assigned to the CDT group, you would also undergo a catheter-directed procedure.

Compensation

Not stated in the trial record.

Follow-up

Your oxygen consumption will be measured at 3 months, and your physical ability will be assessed at 12 months. Major bleeding will be tracked for up to 7 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.